Clinical trials: Locally Advanced Colorectal Cancer
Colorectal Cancer
Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00975897
- Testing
- bevacizumab, cetuximab, fluorouracil
- Where
- 3 sites in United Kingdom
- Volunteers
- 3,240 people
- Sponsor
- Medical Research Council
Phase 2 Study
mFOLFOXIRI Plus Bevacizumab for Organ Preservation in Locally Advanced Rectal Cancer
Neoadjuvant mFOLFOXIRI plus bevacizumab may achieve tumor shrinkage and reduce micrometastases, offering a radiotherapy-free organ-preservation alternative for locally advanced rectal cancer.
- Trial name
- FOBEAR-ii (NCT07817888)
- Testing
- FOLFOXIRI + Bevacizumab
- Volunteers
- 119 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Colorectal Neoplasms
Multi-omics Model Predicts Efficacy of Preoperative Neoadjuvant Chemoradiotherapy Combined PD-1 Antibody Therapy for Locally Advanced Rectal Cancer
The purpose of this clinical research is to establish a multi-omics model based on genomics，transcriptomics，gut microbiota in predicting pathologic response after neoadjuvant chemoradiotherapy combined PD-1 antibody given to…
- Trial name
- NCT05368051
- Testing
- long course radiotherapy + capecitabine + PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Friendship Hospital
Colon Adenocarcinoma, ERBB2 Gene Amplification
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified colorectal cancer that has spread from where it…
- Conditions
- Colon Adenocarcinoma, ERBB2 Gene Amplification, Rectal Adenocarcinoma, Recurrent Colon Carcinoma
- Trial name
- NCT03365882
- Testing
- Cetuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- 798 sites in United States, Puerto Rico
- Volunteers
- 240 people
- Sponsor
- SWOG Cancer Research Network
Rectal Neoplasms
Study for Wait and Watch Suitable in Rectal Cancer
One of the standard treatment options offered to patients of locally advanced rectal cancer is neoadjuvant (treatment given before surgery) radiotherapy \& chemotherapy followed by surgery.
- Trial name
- ARROW (NCT06252142)
- Where
- India
- Volunteers
- 260 people
- Sponsor
- Tata Memorial Centre
Rectal Cancer
Prediction of the Response to Neoadjuvant Radiation Chemotherapy Through Texture Analysis Derived From Medical Imaging
In patient with complete pathological response, surgery could be omitted without compromising progression-free or overall survival. A powerful prediction model is needed to guide management of this population.
- Trial name
- RECTOMICS (NCT04920435)
- Where
- 3 sites in France
- Volunteers
- 124 people
- Sponsor
- University Hospital, Brest
Rectum Cancer, Adenocarcinoma
ADAR1 Expression Level in Rectal Cancer
Total neoadjuvant therapy (TNT) is currently the standard treatment for locally/locally advanced rectal cancer due to better response and fewer distant metastases.
- Trial name
- ADAR1TNT (NCT07108348)
- Testing
- Adenosine deaminase acting on RNA1
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Necmettin Erbakan University
Colorectal Cancer
AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
RATIONALE: AZD2281 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00535353
- Testing
- irinotecan hydrochloride, olaparib
- Where
- 2 sites in Canada
- Volunteers
- 26 people
- Sponsor
- NCIC Clinical Trials Group
Colorectal Cancer (CRC)
Neoadjuvant Therapy （NALIRIFOX） for Locally Advanced Colon and Upper Rectal Cancer
The goal of this clinical trial is to evaluating the efficacy and safety of Oxaliplatin + Irinotecan Liposome + 5-FU/LV in patients with Locally Advanced Colorectal Cancer and Upper Rectal Cancer. Patients would be included as:1.
- Trial name
- HOPE (NCT07020468)
- Testing
- NALIRIFOX
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Affiliated Cancer Hospital of Shantou University Medical College
Locally Advanced Malignant Neoplasm, Rectal Carcinoma
Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma
Locally advanced rectal carcinoma raise the issue of both the oncological control, local and general, and the therapeutic morbidity.
- Trial name
- GRECCAR14 (NCT04749108)
- Testing
- Induction chemotherapy - modified FOLFIRINOX regimen, Early tumor response evaluation by MRI volumetry, Radiochemotherapy Cap 50
- Where
- 30 sites in France
- Volunteers
- 1,075 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Metastatic Colorectal Cancer (CRC), Locally Advanced Colorectal Cancer
Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer
This is a phase 1, open-label, multicentric study evaluating the safety, feasibility and efficacy of ODI-2001, a personnalized therapeutic cancer vaccine composed of DNA neoantigen vaccine, Modified Vaccinia virus Ankara (MVA)…
- Conditions
- Metastatic Colorectal Cancer (CRC), Locally Advanced Colorectal Cancer, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Cancer
- Trial name
- ODI-2001-01 (NCT07587827)
- Testing
- Personalized cancer vaccine including : DNA neoantigen vaccine, MVA viral vector and Ipilimumab (anti-CTLA4)
- Where
- 2 sites in France
- Volunteers
- 77 people
- Sponsor
- Centre Georges Francois Leclerc
Colorectal Cancer
Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients
dMMR/MSI-H colorectal cancer patients are the dominant population of immunotherapy/neoadjuvant immunotherapy, but imaging evaluation of immunotherapy efficacy is insufficient.
- Trial name
- NCT06098560
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Geneplus-Beijing Co. Ltd.
Rectal Cancer, Radiotherapy
Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer
This is a open-label, single-arm study to investigate the safety and efficacy of consolidative chemotherapy with camrelizumab, an anti-PD-1 antibody drug following short course radiotherapy and subsequent surgical therapy in…
- Conditions
- Rectal Cancer, Radiotherapy, Immunotherapy
- Trial name
- NCT04231552
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Advanced Rectal Cancers
Preoperative Chemo-radiation With IG-IMRT Dose Escalation for Locally Advanced Rectal Cancers
Hypothesis : Therapeutic intensification by increasing the dose delivered to the tumor by RCMI (conformational radiotherapy by intensity modulation) in order to reduce local relapse, often associated with poor prognosis Primary…
- Trial name
- RADICAL (NCT03200249)
- Testing
- Preoperative chemo-radiation with IG-IMRT dose escalation
- Where
- 2 sites in France
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Centre Georges Francois Leclerc
Rectal Cancer
Preoperative Combined Induction Chemotherapy With Capecitabine, Oxaliplatin, Bevacizumab and Radiotherapy
Phase II pilot study of a preoperative induction chemotherapy in combination with Bevacizumab followed by combined radiochemotherapy for patients with locally advanced rectal carcinoma
- Trial name
- NCT01434147
- Testing
- preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine
- Where
- 7 sites in Austria
- Volunteers
- 25 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Rectal Cancer
Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer
Despite treatment of locally advanced rectal cancer relapses are frequent. Several attempts to improve these results with therapy intensification have shown modest effect on disease free survival (DFS) and overall survival (OS).
- Trial name
- RECAP (NCT02910843)
- Testing
- Regorafenib, Capecitabine, Radiotherapy
- Where
- 7 sites in Switzerland
- Volunteers
- 25 people
- Sponsor
- Swiss Cancer Institute
Rectal Adenocarcinoma
Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma
The purpose of the study is to determine the feasibility of using magnetic resonance imaging (MRI)-guided adaptive chemoradiation therapy to improve response to treatment.
- Trial name
- NCT05108428
- Testing
- Capecitabine, Radiation Therapy, FOLFOX regimen
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Rectal Adenocarcinoma, Rectal Cancer
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
Rectal cancer patients who do not achieve a complete response to standard of care chemotherapy and radiation often require surgical resection as part of curative intent therapy.
- Trial name
- NCT07292298
- Testing
- High Rare Dose Rectal Brachytherapy Boost
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- University of Colorado, Denver
Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)
This study is a prospective, multi-cohort clinical trial designed to evaluate the preliminary efficacy and safety of zanidatamab in combination with tislelizumab and chemotherapy/radiotherapy for patients with HER2-positive…
- Conditions
- Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (mCRC), Neoadjuvant Therapy
- Trial name
- NCT07243938
- Testing
- short-course radiotherapy, Zanidatamab, Tisleizumab(BGB-A317)
- Volunteers
- 70 people
- Sponsor
- Tao Zhang
Locally Advanced Rectal Cancer
Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study
To investigate the efficacy and safety of short-course radiotherapy sequential fruquintinib in combination with adebrelimab and CAPOX (full course neoadjuvant therapy) in patients with locally advanced rectal cancer.
- Trial name
- NCT06234007
- Testing
- Fruquintinib, Adebrelimab, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology